Las Vegas, NV – March 02, 2015 — (TechSonian) –Cerner Corporation (CERN) is once again the top performing enterprise health information exchange (HIE) supplier for inpatient/ambulatory health information technology, according to Black Book Rankings’ 2015 HIE User Survey. This marks the third consecutive year that Cerner has earned the designation.Cerner was also ranked No. 1 among all HIE suppliers, for: ease of transmittal and exchange; clinical system workflow and output; and quality reporting and communications. Among EHR-centric HIE competitors, Cerner was ranked No. 1 in: HIE stakeholder alignment; widespread integration and flexibility; data analytics and business intelligence; and configurations and interfaces.
In the last trading session, Cerner Corporation (NASDAQ:CERN) traded 1.20 million shares versus the average volume of the stock remained 1.64 million shares. The stock was lost -0.98%, while its ending price was $72.06. The market capitalization of the stock reached 2469 billion.
Has CERN Found The Bottom And Ready To Gain Momentum? Find Out Here
Analog Devices, Inc. (ADI) declared that Vincent Roche, President and Chief Executive Officer, will speak at the Morgan Stanley Technology, Media Telecom Conference in San Francisco, California, on Tuesday, March 3, 2015 at 1:50 p.m. Pacific time.Acknowledged industry-wide as the world leader in data conversion and signal conditioning technology, Analog Devices serves over 100,000 customers, representing virtually all types of electronic equipment.
In the last trading day, Analog Devices, Inc. (NASDAQ:ADI) plunged -0.58% to move at $58.54. The volume of the stock was 1.20 million shares and the average volume remained 1.92 million shares. The stock recorded the day price range of $58.51-$59.04. The beta of the stock remained 1.09.
Why Should Investors Buy ADI After the Recent Fall? Just Go Here and Find Out
BD Life Sciences, a segment ofBecton, Dickinson and Co. (BDX) and Cellular Research, an innovative company focused on enabling high-resolution biology, informed that they will be jointly promoting their unique solutions for highly multiplexed cell isolation and single-cell gene expression analysis.Cellular Research has developed Precise, a highly multiplexed molecular and sample barcoding technology, whereby each transcript in each plated cell is uniquely barcoded during incorporation into one sequencing library. Precise encoding plates can also be multiplexed, enabling up to 4,608 single cells to be prepared into one single sequencing library and reaction.
Becton, Dickinson and Co. (NYSE:BDX) moved on an average-volume of 1.17 million shares in the last trading session. The share price lost -1.23% and reached at $146.72. The market capitalization of the stock remained 28.31 billion. YTD trend of the stock was increased 5.43%.
Why Should Investors Buy BDX After The Recent Gain? Just Go Here and Find Out
UBS Group AG (USA) (UBS) throughout its subsidiaries provides retail, wealth management, corporate and institutional banking, asset management, and investment banking products and services worldwide. The company’s Wealth Management division provides financial services to high net worth individuals. This division offers investment management, estate planning, and corporate finance advice, as well as specific wealth management products and services.This division also provides professional services, including fund set-up, accounting, and reporting for traditional investment funds and alternative funds.
UBS Group AG (USA) (NYSE:UBS) opened the session at $17.57, trading in a range of $17.49-$17.67, and closed at $17.49. The stock showed a positive performance of 0.23% in the last trading session. The stock traded on an average volume of 1.56 million shares.
For How Long UBS will Fight for Profitability? Just Go Here and Find Out
